(186 days)
Not Found
No
The summary describes a topical cream and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The device is described as a cream intended for the management of pruritus and dryness of skin in specific dermatological conditions, which aligns with the function of a therapeutic device.
No
The device is a cream intended for topical application to manage skin conditions, not to diagnose them.
No
The device description explicitly states it is a "non-sterile formulation intended for topical application," indicating it is a physical cream, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The intended use is for the management of pruritus and dryness of skin in allergic contact dermatitis. This is a topical treatment for a skin condition, not a test performed on samples taken from the body to diagnose or monitor a medical condition.
- Device Description: The device is a "non-sterile formulation intended for topical application." This further confirms it's a cream applied to the skin, not a diagnostic test.
- Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting specific analytes or markers
- Providing diagnostic information
The device is clearly intended for therapeutic management of a skin condition through topical application.
N/A
Intended Use / Indications for Use
It is intended for management of pruritus and Dryness of skin in Allergic contact dermatitis. Not to be used on Breached or Compromised skin or open sores.
Product codes (comma separated list FDA assigned to the subject device)
FRO
Device Description
Derma-R Cream is a non-sterile formulation intended for topical application. It is intended for management of pruritus and Dryness of skin in Atopic dermatitis and Allergic contact dermatitis. Not to be used on Breached or Compromised skin or open sores.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Skin
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
No clinical performance testing was provided to demonstrate device safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a seal on the left and the FDA acronym and name on the right. The seal on the left is a circular emblem with an eagle in the center, surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA". To the right of the seal is the FDA acronym in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
September 20, 2024
Raya Pharmaceuticals LLC Parikh Ankur Chief Executive Officer 115 Kings Bay Rd Suite C Kingsland, Georgia 31548
Re: K240722
Trade/Device Name: Derma-R Cream Regulatory Class: Unclassified Product Code: FRO Dated: August 22, 2024 Received: August 22, 2024
Dear Parikh Ankur:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
2
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for Yu-Chieh Chiu, Ph.D. Assistant Director DHT4B: Division of Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Mustafa A.
Mazher -S
Enclosure
3
Indications for Use
510(k) Number (if known) K240722
Device Name Derma-R Cream
Indications for Use (Describe)
It is intended for management of pruritus and Dryness of skin in Allergic contact dermatitis. Not to be used on Breached or Compromised skin or open sores.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510K Summary
In accordance with 21 CFR 807.87(h) and (21 CFR 807.92a), the following summary is provided.
Submitter Information:
- 510(k) Submitter: Raya Pharmaceuticals LLC
- Address: 115 Kings Bay Rd, Suite C, Kingsland, Ga, 31548
- Company Contact Person: Ankur Parikh, CEO ●
- Phone: (904) 386-6785 -
- Fax: 1-877-735-9071 -
- Email: office@rayapharmaceuticals.com -
- Establishment Registration: 3019944216 ●
- Device Common Name: Dressing, Wound, Drug ●
- Device trade or proprietary name: Derma-R Cream ●
- Device Classification: Unclassified
- Device Panel: General & Plastic Surgery
- Device Product Code: FRO
- . Primary Predicate Device 510(k) Number: K090585 Neosalus cream. Device Name: QUINNOVA PHARMACEUTICALS Manufacturer:
Date of Summary Preparation: September 9th, 2024
Device Description
Derma-R Cream is a non-sterile formulation intended for topical application. It is intended for management of pruritus and Dryness of skin in Atopic dermatitis and Allergic contact dermatitis. Not to be used on Breached or Compromised skin or open sores.
Indications for Use
It is intended for management of pruritus and Dryness of skin in Atopic dermatitis and Allergic contact dermatitis. Not to be used on Breached or Compromised skin or open sores.
5
Comparison of Derma-R Cream and Predicate Device Composition
Derma-R used Component with Similar Chemical Characteristics as the predicate Device. Nonclinical tests showed Derma-R was equivalent to the predicate and a non-irritant, non-sensitizer, and non-Cytotoxic.
| Technological Characteristics | Derma-R | Neosalus (K090585) |
|---|---|---|
| Topical Dressing | Same as predicate | Same |
| Dosage form | Cream | Cream |
| Emulsifier | Same as predicate | Same |
| PH Balancer | Same as predicate | Same |
Comparison of Derma-R Cream and Predicate Device in terms of Technological Characteristics
Comparison of Derma-R Cream and Predicate Device in terms of Indication for Use
| Derma-R | Neosalus (K090585) | |
|---|---|---|
| Intended Use and Indication | ||
| for Use | management of pruritus and Dryness of | |
| skin in Atopic dermatitis and Allergic | ||
| contact dermatitis. | Management of various | |
| types of dermatoses, | ||
| including atopic dermatitis | ||
| and allergic contact | ||
| dermatitis. | ||
| Rx Only | ✓ | ✓ |
6
The Following Biocompatibility tests were conducted:
- 1- Cytotoxicity testing, per ISO 10993-5:2009 (In Vitro)
- 2- Skin Sensitization testing, per ISO 10993-23:2021
- 3- Skin irritation testing, per ISO 10993-10:2021
Other Tests:
Microbiology test
- A- USP to Microbial Examination of Non-sterile products: Microbial Enumeration Tests
- B- USP Microbiological Examination of Non-sterile Products: Tests for Specified Microorganisms
- C In Use Stability Study of Derma R Cream, to establish a period of time during which product can be used whilst retaining quality within an accepted specification once the container is opened.
- D- The Preservative effectiveness test, Per USP .
- E- Shelf Life and Stability Tesings.
Clinical Performance Testing
No clinical performance testing was provided to demonstrate device safety and effectiveness.
Conclusion
Based on its formulation for use, as well as the non-clinical testing results showing a similar profile, we conclude that Derma-R Cream is substantially equivalent to its predicate device Neosalus cream.